J Immunol 2002 Nov 1;169(9):5098-108
Sidney J, Del Guercio MF, Southwood S, Sette A.
Epimmune, Inc., San Diego, CA 92121.
Assays to measure the binding capacity of peptides for HLA-DQA1*0501/B*0201 (DQ2.3) and DQA1*0301/B*0302 (DQ3.2) were developed using solubilized MHC molecules purified from EBV-transformed cell lines.
These quantitative assays, based on the principle of the inhibition of binding of a high-affinity radiolabeled ligand, were validated by examining the binding capacity of known DQ-restricted epitopes or ligands.
The availability of these assays allowed an investigation of patterns of cross-reactivity between different DQ molecules and with various common DR molecules.
DQ2.3 and DQ3.2 were found to have significantly overlapping peptide binding repertoires.
Specifically, of 13 peptides that bound either DQ2.3 or DQ3.2, nine (69.2%) bound both.
The molecular basis of this high degree of cross-reactivity was further investigated with panels of single substitution analogs of the thyroid peroxidase 632-645Y epitope.
It was found that DQ2.3 and DQ3.2 bind the same ligands by using similar anchor residues but different registers.
These data suggest that in analogy to what was previously described for HLA-DR molecules, HLA-DQ supertypes characterized by largely overlapping binding repertoires can be defined.
In light of the known linkage of both HLA-DQ2.3 and -DQ3.2 with insulin-dependent diabetes mellitus and celiac disease, these results might have important implications for understanding HLA class II autoimmune disease associations.